title: Biopharma business models in Canada.
abstract: This article provides new insights into the different strategy paths or business models currently being implemented by Canadian biopharma companies. Through a case-study methodology, seven biopharma companies pertaining to three business models were analyzed, leading to a broad set of results emerging from the following areas: activity, business model and strategy; management and human resources; and R&D, technology and innovation strategy. The three business models represented were: model 1 (conventional biotech oriented to new drug development, radical innovation and search for discoveries); model 2 (development of a technology platform, usually in proteomics and bioinformatics); and model 3 (incremental innovation, with shorter and less risky development timelines).
authors.affiliation: Facultad de Economía, Universitat de València, Avda. Tarongers s/n, 46022 Valencia, Spain. Isidre.March@uv.es
authors.forename: I
authors.initials: I
authors.lastname: March-Chordà
authors.forename: R M
authors.initials: RM
authors.lastname: Yagüe-Perales
mesh_terms: D001709:Biotechnology / Q000458:organization & administration*; D002170:Canada; D019295:Computational Biology / Q000379:methods; D015195:Drug Design; D004345:Drug Industry / Q000458:organization & administration*; D006801:Humans; D017146:Models, Organizational; D040901:Proteomics / Q000379:methods; D012106:Research / Q000458:organization & administration